Literature DB >> 17490679

Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics.

Todd E Haim1, Candice Dowell, Theodhor Diamanti, James Scheuer, Jil C Tardiff.   

Abstract

Mutations in cardiac troponin T (cTnT) are linked to a severe form of Familial Hypertrophic Cardiomyopathy. Patients carrying mutations flanking the tropomyosin-binding domain of cTnT (R92L and Delta160E) develop distinct clinical syndromes. In order to better understand the cellular pathophysiology underlying these clinically relevant differences, we studied isolated adult left ventricular myocytes from independent transgenic cTnT mouse lines carrying either a 35% (Delta160E) or 50% (R92L) replacement of the endogenous cTnT with the mutant forms. Measurement of baseline myocellular contraction revealed that the Delta160E cells had significant decreases in the peak rate of contraction and percent shortening as compared to either R92L or Non-TG myocytes. In addition, while both Delta160E and R92L myocytes demonstrated a decrease in the peak rate of relaxation as compared to Non-TG, the magnitude of the difference was significantly greater in Delta160E cells. Concurrent myocyte [Ca2+](i) transient measurements revealed that while the alterations in the peak rates and times of the rise and decline of the [Ca2+](i) transient were similar to the changes in the respective measures of sarcomeric mechanics, R92L cells also exhibited reduced rates of the rise and decline of the [Ca2+](i) transient but did not exhibit these reductions in terms of sarcomeric mechanics. Of note, only Delta160E, and not R92L myocytes, demonstrated significant reductions in SR Ca2+ load and uptake, corresponding to the impairments seen in the [Ca2+](i) and mechanical transients. Finally, Western analysis revealed a significant Delta160E-specific reduction in the SERCA2a/PLB ratio, which may well underlie the observed alterations in Ca2+ homeostasis. Therefore, independent cTnT mutations result in significant mutation-specific effects in Ca2+ handling that may, in part, contribute to the observed clinical variability in cTnT-related FHC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490679     DOI: 10.1016/j.yjmcc.2007.03.906

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  31 in total

Review 1.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

2.  HCM-linked ∆160E cardiac troponin T mutation causes unique progressive structural and molecular ventricular remodeling in transgenic mice.

Authors:  Rachel K Moore; Lauren Tal Grinspan; Jesus Jimenez; Pia J Guinto; Briar Ertz-Berger; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2013-02-19       Impact factor: 5.000

Review 3.  Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.

Authors:  Jeffrey R Moore; Leslie Leinwand; David M Warshaw
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

Review 4.  Cell biology of sarcomeric protein engineering: disease modeling and therapeutic potential.

Authors:  Brian R Thompson; Joseph M Metzger
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

Review 5.  Thin filament mutations: developing an integrative approach to a complex disorder.

Authors:  Jil C Tardiff
Journal:  Circ Res       Date:  2011-03-18       Impact factor: 17.367

6.  Independent modulation of contractile performance by cardiac troponin I Ser43 and Ser45 in the dynamic sarcomere.

Authors:  Sarah E Lang; Jennifer Schwank; Tamara K Stevenson; Mark A Jensen; Margaret V Westfall
Journal:  J Mol Cell Cardiol       Date:  2014-12-03       Impact factor: 5.000

7.  Cardiac myosin heavy chain isoform exchange alters the phenotype of cTnT-related cardiomyopathies in mouse hearts.

Authors:  Ron Rice; Pia Guinto; Candice Dowell-Martino; Huamei He; Kirsten Hoyer; Maike Krenz; Jeffrey Robbins; Joanne S Ingwall; Jil C Tardiff
Journal:  J Mol Cell Cardiol       Date:  2009-12-31       Impact factor: 5.000

Review 8.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

9.  Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies.

Authors:  Raffaella Lombardi; Achim Bell; Vinitha Senthil; Jasvinder Sidhu; Michela Noseda; Robert Roberts; Ali J Marian
Journal:  Cardiovasc Res       Date:  2008-03-18       Impact factor: 10.787

10.  Mechanical and energetic properties of papillary muscle from ACTC E99K transgenic mouse models of hypertrophic cardiomyopathy.

Authors:  Weihua Song; Petr G Vikhorev; Mavin N Kashyap; Christina Rowlands; Michael A Ferenczi; Roger C Woledge; Kenneth MacLeod; Steven Marston; Nancy A Curtin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-19       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.